A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 31, 2000

Study Completion Date

December 31, 2002

Conditions

Lung Cancer

Interventions

DRUG

Inhaled Budesonide 800 µg twice daily

Trial Locations (1)

British Columbia Cancer Agency, Vancouver

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of British Columbia

OTHER

NCT00175747 - A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) | Biotech Hunter | Biotech Hunter